Yuehong Li

Yuehong Li

Auto-generated profile, based on publicly available information

Yuehong Li

The Second Hospital of Hebei Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2019 in Oncology Reports
Verified
Journal Article
Open access
JZJing Zuo
Jing Zuo
MZMei Zhao
Mei Zhao
BLBowei Liu
Bowei Liu
XHXiaojing Han
Xiaojing Han
YLYuehong Li
Yuehong Li
XZXianghong Zhang
Xianghong Zhang
Intrinsic and acquired resistance of cancer to radio‑and chemotherapy is one of the major challenges in the treatment of esophageal squamous cell carcinoma (ESCC). Elevated reactive oxygen species (ROS) play an important role in the resistance to cisplatin in ESCCs. Super dismutase [Mn], mitochondrial (SOD‑2), an important primary antioxidant enzyme located in mitochondria, could regulate ROS production. Our previous study showed that tumor necrosis factor‑α (TNF‑α)‑mediated SOD‑2 through NF‑κB was involved in epithelial‑mesenchymal transition and migration in A549 cells. Therefore, the present study aimed to identify if TNF‑α mediated SOD‑2 upregulation is involved in cisplatin resistance in ESCC. It was identified that a higher expression of SOD‑2 in human ESCC samples was associated with TNF‑α expression and poor overall survival in patients with ESCC, suggesting that SOD‑2 may act as an oncogene in ESCC. To further confirm if TNF‑α could upregulate SOD‑2 to contribute to cell proliferation, the human ESCC cell line Eca‑109 was treated with TNF‑α in vitro. TNF‑α could upregulate SOD‑2 and induce cell proliferation in Eca109 cells, while blocking SOD‑2 using small interfering RNA (siRNA) inhibited TNF‑α‑induced cell proliferation. Upregulation of SOD‑2 by TNF‑α was inhibited by blocking the NF‑κB pathway, which suggested that SOD‑2 by TNF‑α/NF‑κB contributes to cell proliferation in Eca109 cells. Furthermore, it was observed that TNF‑α could induce cisplatin resistance in Eca109 cells, while transfection with SOD‑2 siRNA could significantly increase the chemosensitivity of ESCC to cisplatin. Therefore, the present results suggested that SOD‑2 may serve as an oncogene, and the upregulation of SOD‑2 by TNF‑α/NF‑κB may contribute to cisplatin resistance in ESCC.

6 August 2021 in Medicine
Verified
Journal Article
Open access
XCxiaojing Chang
xiaojing Chang
YLYuehong Li
Yuehong Li
XXxiaoying Xue
xiaoying Xue
ZHZhou Huandi
Zhou Huandi
LHLiubing Hou
Liubing Hou
Objective: Alveolar soft part sarcomas (ASPS) which has high potential ability of metastasis, is a rare and slowly growing malignant tumor, and mainly primary localized in limbs. To date, little is known about the best treatment of ASPS. This study aims to review the current management and advance of ASPS. Methods: WANFANG MED ONLINE, CNKI, and NCBI PUBMED were used to search literature spanning from 1963 to 2020, and all cases of ASPS about “ASPS, diagnosis, treatment, surgery, radiotherapy, chemotherapy, target therapy or immune therapy” with detailed data were included. Results: Complete surgical resection remained the standard management strategy, radiotherapy was reported to be used for the patients of micro- or macroscopical incomplete residue or the surgical margin was questionable. Chemotherapy was controversial. Some target drugs and immune checkpoint inhibitors had produced antitumor activity. Conclusion: Complete surgical resection is the cure treatment for ASPS, and adjuvant chemotherapy is not recommended excepted clinical trials. For the patients with micro- or macroscopical incomplete residue, radiotherapy should be appreciated. Furthermore, for recurrence, distant metastasis, and refractory of ASPS, combination therapy, especially combination with multiple target agents and/or immune checkpoint inhibitors may prolong survival time.

1 January 2025 in Biochemistry and Cell Biology
Verified
Journal Article
Closed access
LLLi-Yun Liu
Li-Yun Liu
LTLiang Tian
Liang Tian
LGLing-Huan Gao
Ling-Huan Gao
HCHai-Jun Cui
Hai-Jun Cui
XLXue-Mei Li
Xue-Mei Li
YLYue-Hong Li
Yue-Hong Li
E2F transcription factor 8 (E2F8) is an important regulator of the cell cycle. In this study, we first assessed the expression of E2F8 in bladder cancer and examined its effects in the malignant phenotypes of bladder cancer cell lines. We found that E2F8 was upregulated in bladder cancer tissues, and the increased expression was positively associated with higher clinical stage. E2F8 knockdown suppressed bladder cancer cell proliferation, accompanied by the performance of G1 phase arrest and the upregulated Cyclin D1 protein expression. The migrative and invasive capability was reduced in E2F8-depleted bladder cancer cells. Cisplatin resistance is an important cause of bladder cancer relapse. E2F8 downregulation facilitated cisplatin-induced apoptosis of bladder cancer cells. MCM7 is regulated by E2F and has been shown to participate in bladder cancer. There was a positive correlation between E2F8 and MCM7 expression in bladder cancer. We confirmed that E2F8 bound to the promoter region of MCM7 and activated MCM7 transcription. MCM7 overexpression abrogated the suppressive effects of E2F8 knockdown on malignant phenotypes of bladder cancer cells. We also demonstrated that E2F8 knockdown suppressed bladder cancer progression in vivo. In conclusion, we verify that E2F8 functioned in bladder cancer, and might exert its function via MCM7.